NMN Is Expected To Treat PD - News

NMN Is Expected To Treat PD

Oct 09, 2022 / Author: China Glutathione suppliers & NMN manufacturers

Aging will bring many manifestations, such as the loss of muscle control, memory loss, etc. Among them, Parkinson's disease is one of our common elderly diseases.

Recently, the results of a clinical trial on NMN were published, and it was found that changes in NAD+ levels are associated with Parkinson's disease and may be a new way to treat Parkinson's disease.

Parkinson's disease (PD) affects 1%–2% of the population over the age of 65, is a leading cause of death and disability, and has a rapidly growing global socioeconomic impact.

Current treatments for PD can provide partial symptom relief, primarily targeting motor symptoms, but have no substantial effect on disease progression. Although several candidate neuroprotective therapies have shown encouraging preclinical results, these therapies have failed to show disease-modifying effects in clinical trials.

There is growing evidence that increasing intracellular levels of nicotinamide adenine dinucleotide (NAD) may play a neuroprotective role in healthy aging and neurodegeneration.

In its oxidized and reduced states, NAD constitutes an essential cofactor for metabolic redox reactions including mitochondrial respiration. In addition, NAD+ is a substrate involved in important signaling reactions such as DNA repair, histone and other protein deacylation reactions.

Therefore, the research team guessed that NAD+ may be a potential neuroprotective agent for Parkinson's disease, so they conducted a double-blind phase I clinical trial to study the effect of NAD+ on PD.

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease

The study recruited 30 men and women with an average age of 60 years and older, and no adverse events occurred during the experiment.

Some time after the start of the experiment, the test found that NAD+ levels increased in the brain of the NMN group, and the brain NAD response was heterogeneous, so this change increased the possibility of heterogeneous treatment.

NMN Is Expected To Treat PD

The subjects' brains were then scanned, and changes in NRRP expression were found to be significantly correlated with changes in UPDRS motor scores recorded at PET, that is, an increase in NAD+ induced a new metabolic network.

NMN Is Expected To Treat PD

Increased NAD+ induces upregulation of biological processes, including proteasome function, RNA transport, and stability. Highly significant upregulation of multiple biological processes was revealed, including ribosomal, proteasome, lysosomal and mitochondrial pathways.

NMN Is Expected To Treat PD

Several inflammatory cytokines were reduced, and indicators of neuronal damage were not reduced, which confirmed safety.

Research on NAD+ will continue, and there will be more good news about NMN in the future. However, although NMN has important physiological effects on the human body, for the sake of safety, it is recommended to take it after pregnancy and lactation.

Tag: NMN

Supplier Introduction: China glutathione supplier and NMN manufacturer GSHworld, the company mainly develops biotechnology and industrialization. As a global pioneer in enzymatic catalytic ATP regeneration technology, our company advocates green production and is committed to providing customers with better and more environmentally friendly products and services. Glutathione Manufacturer,NMN Factory,Citicoline Sodium supplier,China NMN manufacturers

Related Products

Related News

Product Recommended

  • High Density Glutathione suppliers & manufacturers in China
  • L-Glutathione Oxidized suppliers & manufacturers in China
  • S-Acetyl-L-Glutathione suppliers & manufacturers in China
  • β-Nicotinamide Mononucleotide suppliers & manufacturers in China
  • L-Carnosine suppliers & manufacturers in China
  • Ademetionine Disulfate Tosylate Powder suppliers & manufacturers in China